Biopharmaceutical platform corporation Alteogen announced on the 8th that it has been invited to participate in the 'J.P. Morgan Healthcare Conference' to be held in San Francisco, United States, from the 13th to the 16th.
This is the first time Alteogen has received a formal invitation to the J.P. Morgan Healthcare Conference, and it will be the company's first conference participation following the announcement of the phase 3 top line results for the subcutaneous formulation anticancer drug 'Keytruda SC.'
Alteogen plans to hold face-to-face meetings to strengthen cooperation with existing partners at the event, as well as meet with corporations looking to resume discussions and new potential partners. A company official noted, 'Interest from corporations has increased as the technology has been validated following the completion of phase 3 for the first therapeutic using the Hybrozyme platform, and we are engaging with more companies. We will strive to turn this interest into tangible results during this event.'
Last year, Alteogen signed new contracts to replace existing agreements with U.S. Merck (MSD) and Swiss Sandoz, which expressed a desire to use the Hybrozyme™ platform for the development of subcutaneous formulation therapeutics. Additionally, it entered into a technology transfer agreement with Japan's Daiichi Sankyo for the development of subcutaneous antibody-drug conjugates (ADCs). Notably, MSD announced that it achieved its indicators by summarizing the main results following the completion of the phase 3 trial for the subcutaneous formulation of Keytruda, which applied the Hybrozyme platform technology.